Download Files:
Dabuzalgron
$155 – $280
Products Details
Product Description
– Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1].
Web ID
– HY-117071
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C12H16ClN3O3S
References
– [1]Beak J, et al. An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity. JACC Basic Transl Sci. 2017 Feb;2(1):39-53.
CAS Number
– 219311-44-1
Molecular Weight
– 317.79
Compound Purity
– 98.72
SMILES
– CS(=O)(NC1=C(Cl)C=CC(OCC2=NCCN2)=C1C)=O
Clinical Information
– No Development Reported
Research Area
– Endocrinology; Cardiovascular Disease
Solubility
– DMSO : 26 mg/mL (ultrasonic)
Target
– Adrenergic Receptor;Apoptosis
Isoform
– α adrenergic receptor
Pathway
– Apoptosis;GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
